

la Renon

# TRINITY IN SYNC



Now Available

**SITAHENZ-GM** 50/1/500  
50/2/500

Sitagliptin 50 mg + Glimepiride 1 mg / 2 mg + Metformin 500 mg Tablets

Also Available

**SITAHENZ-GM** 50/1/1000  
50/2/1000

Sitagliptin 50 mg + Glimepiride 1 mg / 2 mg + Metformin 1000 mg Tablets

# SITAHENZ-GM

## BACKGROUND

Type 2 diabetes is caused by the body's inability to respond appropriately to the effect of insulin secreted by pancreas. Progressive  $\beta$ -cell failure and insulin resistance are the main nuclear defects responsible for the development and progression of hyperglycemia in individuals with T2DM. Patients with type 2 diabetes mellitus (T2DM) often require multiple therapies to achieve glycemic control. As per American Diabetes Association and the European Association for the Study of Diabetes, metformin is the first drug of choice for type 2 diabetes, and DPP-4 inhibitors are cited as one of second-line drugs. Combination therapy with a dipeptidyl peptidase-4 (DPP-4) inhibitor, metformin and sulfonylurea results in substantial and additive glucose-lowering effects in patients with T2DM.

## INDICATION

**Sitahenz-GM** is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type-2 diabetes whose diabetes are not adequately controlled with dual therapy and require additional glycemic control.

## MECHANISM OF ACTION

### Sitagliptin

**Sitagliptin** selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulintropic peptide to facilitate glucose regulation in response to a meal.

### Glimepiride

**Glimepiride** is an insulin secretagogue and, like other sulfonylureas, is only effective in patients with residual pancreatic beta-cell activity. The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells.

### Metformin

**Metformin** improves glucose tolerance in patients with type-2 diabetes, lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

## DOSAGE

**Sitahenz-GM 50/1/500 & 50/2/500:** 1-2 Tablet a day orally or as prescribed by the doctor.

**Sitahenz-GM 50/1/1000 & 50/2/1000:** 1 Tablet a day orally or as prescribed by the doctor.

References:  
1. Diabetes Ther (2017) 8:251-273  
2. Medicine Science 2019;8(3):687-91

## La Renon Healthcare Private Limited

207-208, Iscon Elegance, Circle P, Prahlad Nagar Cross Road,  
S.G. Highway, Ahmedabad - 380015, Gujarat, India.  
Phone: +91 79 6616 8998, 2693-6656 | Fax: +91 79 6616 8998  
Email: info@larenon.com | Web: www.larenon.com

©2025 All Rights Reserved, La Renon Healthcare Private Limited



Scan QR for more  
Prescribing Information

I am:	<input type="text"/>
Call me on:	<input type="text"/>
Mail me at:	<input type="text"/>